ArticleCell death discovery2026
SNORD60-mediated 2'-O-methylation of KCP enhances ferroptosis sensitivity in hepatoblastoma.
Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Ferroptosis has increasingly emerged as a novel target for cancer therapy because of intrinsic or acquired ferroptosis vulnerabilities in cancers. Small nucleolar RNA (snoRNA)-mediated mRNA modifications play a critical role in regulating ferroptosis and supporting tumor cell adaptation. However, the function and mechanism of the box C/D snoRNA SNORD60 in hepatoblastoma (HB) remain poorly understood. Here, we found that SNORD60 expression was markedly downregulated in HB tissues, and restoring its expression inhibited HB cell proliferation and induced ferroptosis both in vitro and in vivo. Mechanistically, SNORD60 guided the 2'-O-methylation (Nm) of kielin/chordin-like protein (KCP) mRNA, and accelerated its degradation by resolving a G-quadruplex proximal to the Nm site. Furthermore, Silencing KCP induced lipid peroxidation and ferroptosis by suppressing ATF4-mediated transcription of SLC7A11. Moreover, plasma KCP protein levels were markedly higher in patients with HB than in healthy individuals, supporting KCP as a reliable non-invasive diagnostic biomarker for HB. High KCP expression correlates with poor patient prognosis. Overall, our findings reveal that SNORD60-mediated Nm modification of KCP prevents tumor cells from evading ferroptosis and inhibits tumor progression. This SNORD60/KCP axis represents a novel ferroptosis vulnerability and a promising therapeutic target in HB.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.